Research

School of Pharmacy tops pharmacy schools in NIH funding for 39th straight year

Wed Feb 27, 2019

Kroetz and colleague review the results of an experiment

Deanna Kroetz, PhD (right) was among dozens of faculty members who contributed to the School of Pharmacy becoming the top recipient of NIH funding among all pharmacy schools in 2018.

Among all U.S. pharmacy schools, the UCSF School of Pharmacy earned the most research funding from the National Institutes of Health in 2018, totaling nearly $29 million dollars that will support studies spanning the basic to the clinical sciences.

USP/UCSF fellowship to support research in the quality and safety of medical products

Wed Feb 27, 2019

The UCSF Fellowship in Quality of Medical Products will support research into excipients, or inactive ingredients found in pharmaceutical drugs.

A new fellowship, funded jointly by UCSF-Stanford CERSI and the U.S. Pharmacopeial Convention (USP), will support research into the inactive components of medications, which are known as excipients.

Creating an inexhaustible database for drug molecules

Mon Feb 11, 2019

Elisabeth Fall

Brian Shoichet, PhD, brought his drug discovery software to an enormous database of small molecules.

School of Pharmacy researchers helped a free public database of potential drug molecules grow 100-fold.

Tamraz is featured PGRN Investigator

Tue Feb 5, 2019

Elisabeth Fall

Bani Tamraz, PharmD, PhD, is the featured Pharmacogenomics Research Network Investigator (PGRN) for February 2019. An article on the group’s website described his overall goal to build a patient-oriented program of pharmacogenetics research, teaching, and clinical practice that utilizes genetics...

QBI fellowship fosters curiosity and perseverance for women scientists

Mon Jan 28, 2019

QBI

Jacqueline Kyosiimire-Lugemwa, PhD, was the first recipient of QBI’s Scholarship for Women from Developing Nations in Biosciences.

Jacqueline Kyosiimire-Lugemwa, the first recipient of QBI’s Scholarship for Women from Developing Nations in Biosciences, spent a year at UCSF in which her perseverance in the sciences was tested. She recently returned to her home country of Uganda more ready than ever to tackle big questions about...

CRISPR-based obesity treatment shows promise for other diseases

Thu Jan 17, 2019

Ahituv, right, works in his lab with postdoc Fumitaka Inoue

Susan Merrell

Nadav Ahituv, PhD, right, was able to curb obesity in mice by tweaking two genes involved in controlling appetite.

A recent study by Nadav Ahituv, PhD, showed that obesity caused by a gene mutation could be treated in animal models.

Keiser receives $2.5 million to apply machine learning towards new therapies for Alzheimer’s, Parkinson’s

Tue Jan 8, 2019

UCSF

Michael Keiser, PhD, received a Ben Barres Early Career Acceleration Award from the Chan Zuckerberg Initiative, which will support his research into novel therapies for neurodegeneration.

Michael Keiser, PhD, received a Ben Barres Early Career Acceleration Award from the Chan Zuckerberg Initiative, which will fund his research into novel therapies for neurodegeneration.

Combination drug therapy overcomes drug-resistant lung cancer in the lab

Wed Dec 19, 2018

National Cancer Institute

A chest x-ray showing a possible lung cancer tumor (National Cancer Institute)

Many types of lung cancer thwart even the most targeted of therapies due to drug resistance, but a group of UCSF scientists led by Sourav Bandyopadhyay, PhD, have now shown that adding a second drug into treatment regimens can overcome this resistance in lab-grown, lung cancer cell lines.

QBI scientists decipher how Ebola, dengue, and Zika infect human cells

Fri Dec 14, 2018

Chris Goodfellow (Gladstone Institutes)

Nevan Krogan, PhD, senior author on the two studies and director of QBI

In a pair of recent studies, scientists at the Quantitative Biosciences Institute uncovered how Ebola, dengue, and Zika hijack human proteins to infect human cells, findings that point to new approaches for treating these diseases.

Research points to individualized treatments for curing TB

Tue Nov 20, 2018

Rada Savic, PhD, senior author on the study, presented her team's work on tuberculosis treatments at the 49th Union World Conference on Lung Health in The Hague, The Netherlands, in late October 2018.

Tuberculosis is usually treated with a six month regimen of daily antibiotics, but millions of patients do not recover from the disease during treatment. Rada Savic’s team showed that adjusting the duration of this regimen based on disease severity could lead to better outcomes.

Categories: Research